Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects of genetic analysis-guided dosing of
paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and
irinotecan hydrochloride (FOLFIRABRAX) in treating patients with gastrointestinal cancer that
has spread to other parts of the body and usually cannot be cured or controlled with
treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Genetic analysis may help doctors
determine what dose of irinotecan hydrochloride patients can tolerate.